174 related articles for article (PubMed ID: 2515974)
1. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon.
Wollersheim H; Thien T; Hoet MH; Van Venrooy WJ
Eur J Clin Invest; 1989 Dec; 19(6):535-41. PubMed ID: 2515974
[TBL] [Abstract][Full Text] [Related]
2. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
[TBL] [Abstract][Full Text] [Related]
3. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
Kallenberg CG
Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
[TBL] [Abstract][Full Text] [Related]
4. Raynaud's phenomenon as an early sign of connective tissue diseases.
Kallenberg CG
Vasa Suppl; 1992; 34():25-8. PubMed ID: 1529414
[TBL] [Abstract][Full Text] [Related]
5. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD).
Bodolay E; Csiki Z; Szekanecz Z; Ben T; Kiss E; Zeher M; Szücs G; Dankó K; Szegedi G
Clin Exp Rheumatol; 2003; 21(3):313-20. PubMed ID: 12846049
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease.
Vayssairat M; Baudot N; Gaitz JP
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):747-9. PubMed ID: 7722019
[TBL] [Abstract][Full Text] [Related]
8. Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD).
De Angelis R; Cerioni A; Del Medico P; Blasetti P
Clin Rheumatol; 2005 Apr; 24(2):145-51. PubMed ID: 15351873
[TBL] [Abstract][Full Text] [Related]
9. Outcome of positive antinuclear antibodies in individuals without connective tissue disease.
Myckatyn SO; Russell AS
J Rheumatol; 2003 Apr; 30(4):736-9. PubMed ID: 12672192
[TBL] [Abstract][Full Text] [Related]
10. Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon.
Falcini F; Rigante D; Candelli M; Martini G; Corona F; Petaccia A; La Torre F; Raffaele CG; Matucci Cerinic M
Clin Rheumatol; 2015 Jan; 34(1):167-9. PubMed ID: 25428518
[TBL] [Abstract][Full Text] [Related]
11. Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.
Pavlov-Dolijanovic S; Damjanov NS; Vujasinovic Stupar NZ; Radunovic GL; Stojanovic RM; Babic D
Rheumatol Int; 2013 Apr; 33(4):921-6. PubMed ID: 22821334
[TBL] [Abstract][Full Text] [Related]
12. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.
Marasini B; Gagetta M; Rossi V; Ferrari P
Ann Rheum Dis; 2001 Nov; 60(11):1046-9. PubMed ID: 11602476
[TBL] [Abstract][Full Text] [Related]
13. Capillary microscopy is a potential screening method for connective tissue disease in children with Raynaud's phenomenon.
Farenhorst CA; Roon AM; Gessel AI; Stel AJ; Bootsma H; Armbrust W; Mulder DJ
Pediatr Rheumatol Online J; 2022 Feb; 20(1):11. PubMed ID: 35135560
[TBL] [Abstract][Full Text] [Related]
14. The evolution of Raynaud's phenomenon: a longterm prospective study.
Luggen M; Belhorn L; Evans T; Fitzgerald O; Spencer-Green G
J Rheumatol; 1995 Dec; 22(12):2226-32. PubMed ID: 8835553
[TBL] [Abstract][Full Text] [Related]
15. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study.
Yunus MB; Hussey FX; Aldag JC
J Rheumatol; 1993 Sep; 20(9):1557-60. PubMed ID: 8164214
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease.
Groen H; Wichers G; ter Borg EJ; van der Mark TW; Wouda AA; Kallenberg CG
Am J Med; 1990 Jul; 89(1):34-41. PubMed ID: 2368791
[TBL] [Abstract][Full Text] [Related]
17. Raynaud's phenomenon.
Hughes M; Herrick AL
Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):112-32. PubMed ID: 27421220
[TBL] [Abstract][Full Text] [Related]
18. Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis.
Ingegnoli F; Ughi N; Crotti C; Mosca M; Tani C
Swiss Med Wkly; 2017; 147():w14506. PubMed ID: 28975961
[TBL] [Abstract][Full Text] [Related]
19. [Standardized diagnosis and treatment of undifferentiated connective tissue disease and mixed connective tissue disease].
Mo YQ; Yan Q; Ye S; Dai L; Zhao Y
Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1119-1127. PubMed ID: 36207966
[TBL] [Abstract][Full Text] [Related]
20. Associations of nailfold capillary abnormalities and immunological markers in early Raynaud's phenomenon.
Schlager O; Kiener HP; Stein L; Hofkirchner J; Zehetmayer S; Ristl R; Perkmann T; Smolen JS; Koppensteiner R; Gschwandtner ME
Scand J Rheumatol; 2014; 43(3):226-33. PubMed ID: 24517537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
